Skip directly to content

Pfizer UK removes sales incentives for Anti-Infectives field-force in line with commitment to Antimicrobial Stewardship

Pfizer UK has announced an important change to how it incentivises its Anti-Infectives field-force as part of its commitment to the fight against Antimicrobial Resistance (AMR). Effective immediately, all sales have been ‘de-linked’ from its Anti-Infectives (AI) field-force incentives.


Field-force colleagues in the UK will now be measured through Management-Based Objectives (MBOs) – focusing on generating access to medicines and promoting the appropriate use of antibiotics.

The world is facing a large and growing problem due to infections caused by bacterial pathogens that are becoming increasingly resistant to existing antibiotics. An industry Declaration on Antimicrobial Resistance was announced at the World Economic Forum in Davos in 2016. As one of the original signatory companies of the Davos Declaration, Pfizer joined other pharmaceutical companies in endorsing the Roadmap for Progress on Combating Antimicrobial Resistance.1 Pfizer has since undertaken significant anti-microbial stewardship (AMS) activities, demonstrating its commitment to combatting AMR and encouraging good AMS. Today’s change to the UK AI incentives policy is another example of Pfizer’s commitment to the delivery of the Roadmap.

For years, Pfizer has been working with key UK governmental stakeholders to assess how stewardship can be improved.  We are proud to have made this change to our incentives model which has been a goal of ours since signing the Davos Declaration.

Following the recent news from the Department of Health and Social Care that NICE will be leading a UK trial with NHS England and NHS Improvement to evaluate a new ‘subscription’ style payment model there was no better time to implement the changes we have been working towards.

Combatting resistant infections will take commitment and close collaboration with industry, government, NHS and other healthcare organisations – Pfizer stands ready to play its part.”

Susan Rienow, Hospital Business UK Lead, Pfizer UK

Globally, AMR causes 700,000 deaths annually, and in an international review led by Lord O’Neill, it is estimated that this figure could rise to 10 million deaths per year by 2050, which would exceed estimates of deaths caused by cancer.2 The role of anti-infectives and vaccines underpin modern medicine as we know it, curing and even preventing many kinds of infections.2,3

Pfizer has one of the industry’s largest and most diverse portfolio of antimicrobials and as such, has an important role to play in the fight to tackle AMR. Pfizer wants to ensure that patients continue to benefit from the appropriate use of antibiotics so that they work to fight infections in the way that they should. We are deeply committed to working closely with the infectious disease community to address AMR.





  1. Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance January 2016. 
  2. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016.
  3. Dr Diane Ashiru-Oredope. (2015). Antibiotic Resistance: why the fuss and what simple actions can everyone take? January 2015



PP-PFE-GBR-1963 / September 2019